Gary Lyman, MD, MPH, Professor of Medicine and senior lead for quality and policy at the Hutchinson Institute for Cancer Outcomes Research, explains that it may take 8-12 years to prove that biosimilars should be trusted in everyday clinical practice. We discuss the many barriers to biosimilars uptake such as physicians’ education, their concerns about
Andrew Renda, MD, associate vice president of population health at Humana, discusses ways in which Humana designs supplemental benefits for social needs as well as addresses social determinants of health to close clinical gaps in care. I was so curious what payers are trying to do to improve compliance for patients especially as drug prices
David Fajgenbaum, MD, MBA, MSc, survivor of Castleman disease and author of “Chasing My Cure,” discusses treating his own disease through experimental self-administered therapies, involvement in developing the first NCCN guidelines and FDA-approved drugs for Castleman disease, and how to effectively and systematically use off-label drugs for orphan diseases.
Matt Kalaycio, MD, a phenomenal leukemia specialist at the Cleveland Clinic, simplifies initial therapy and monitoring decisions for CML, financial implications for patients treated with TKIs, and treatment choices dictated by payers for patients with specific characteristics. I recall the first presentation I have ever heard about Gleevec at a plenary session at ASH. Amazing
Carla Tardif, CEO of Family Reach, sits down with me to discuss the personal expenses that patients with cancer and their families are burdened with aside from medical care as well as the ways in which Family Reach is offering financial support for these families. What can be done to help patients navigating the expenses
Anita Gruninger, RN and certified case manager, provides the often-forgotten perspective of a caregiver, including the emotional and financial toll a cancer diagnosis has on patients and their caregivers as well as the struggles of navigating the health care system. Caregivers of cancer patients go through much emotional and physical turmoil, but they are rarely
Toni Choueiri, MD, Professor of Medicine at Harvard Medical School, prolific researcher with hundreds of peer-reviewed articles in the most prestigious journals in the world, a kidney cancer specialist at the Dana-Farber Cancer Institute, and Director of the GU oncology program there, sits with me to discuss surgical considerations and multidisciplinary care for localized kidney
Aaron Gerds, MD, department of hematology and medical oncology, Cleveland Clinic, describes the benefits and pitfalls of Twitter as a platform for doctors to share their ideas and engage in the “ultimate peer-review process.” It’s fair to say that social media has transformed the way we communicate forever. So, what are the pluses and minuses
the award-winning hematologist and a medical oncologist who hosted Outspoken Oncology, a podcast featuring candid discussions of the most pressing, and often controversial, medical topics. Combining his background in cancer research and health care advocacy, Dr. Nabhan brings a unique and powerful perspective to current medical events.
